“Warren Buffett once wrote that value investing is like an inoculation--it either takes or it doesn’t--and when you explain to somebody what it is and how it works and why it works and show them the returns, either they get it or they don’t.”
-Seth Klarman of the Baupost Group
In response to a piece penned by Tom Brown of bankstocks.com about Synovus Financial, I carefully go through his bullish arguments and point out areas in which we do not share the same outlook. Tom Brown is an experienced analyst who has far more experience than I have. Accordingly, this is absolutely not an attempt to undermine his work. However, after digging into the credit trends I came to different conclusions about the near term prospects for SNV. Despite this fact, I actually do agree with Brown that that over the next few years there is the potential for the shares to appreciate meaningfully. But, in trying to assess the potential risks, the questions I try to answer are as follows: (1) Will SNV have enough capital to make it through the cycle without further diluting shareholders and (2) What is the probability that SNV does not survive this credit cycle?
As of February 2012, all future posts from The Inoculated Investor will appear at http://covestreetcapital.com/Blog/?cat=14. Please visit the site to subscribe to Cove Street Capital's blog.
Feel free to email me at inoculatedinvestor@gmail.com if you have any comments or questions.
You can also follow me or contact me on Twitter: InoculatedInves